CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma

Journal of Neuro-Oncology

Volumn 89, Issue 2, 2008, Pages 231-238

  Chamberlain, Marc C ^a,b   Glantz, Michael J ^c,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

CPT 11; Recurrent anaplastic oligodendroglioma; Temozolomide refractory

Indexed keywords

ATROPINE; CARMUSTINE; DEXAMETHASONE; DOLASETRON MESILATE; GRANISETRON; IRINOTECAN; LOPERAMIDE; ONDANSETRON; PROCHLORPERAZINE; TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CENTER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG TREATMENT FAILURE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HUMAN; INFECTION; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC EXAMINATION; NEURORADIOLOGY; NEUROSURGERY; NEUTROPENIA; OLIGODENDROGLIOMA; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER; THROMBOCYTOPENIA; THROMBOPHLEBITIS; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CAMPTOTHECIN; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; DACARBAZINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGODENDROGLIOMA; SURVIVAL ANALYSIS;

EID: 48749085863     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9613-6     Document Type: Article

References (44)

1. The Medical Research Council brain tumor working party (2000) Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council Trial. J Clin Oncol 19:509-518
2. Prados MD, Scott C, Curran WJ et al (1999) Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of Radiation Therapy Oncology Group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol 17:3389-3395
3. Westphal M, Hilt DC, Bortey E et al (2003) A phase 3 trial of local chemotherapy with biodegradable Carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5(2):79-88
4. Grossman SA, O'Neill A, Grunnet M, Mehta M et al (2003) Phase III Study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 21:1485-1491
5. Prados MD, Levin V (2000) Biology and treatment of malignant glioma. Semin Oncol 27(Suppl 3):1-10
6. Gutin PH, Prados MD, Phillips TL et al (1991) External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG Study 6G82-2. Int J Radiat Oncol Biol Phys 21:601
7. Loeffler JS, Alexander E, Shea WM et al (1992) Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol 10(9):1379-1385
8. Prados MD, Gutin PH, Phillips TL et al (1992) Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: The UCSF experience. Int J Radiat Oncol Biol Phys 24:593
9. Levin VA, Silver P, Hannigan J et al (1990) Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18:321-324
10. Glioma Meta-analysis Trialists Group (2002) Chemotherapy in adult high-grade glioma: A systemic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 359:1011-1018
11. Fine HA, Dear KB, Loeffler JS et al (1993) Meta-analysis of radiation therapy and without chemotherapy for malignant gliomas in adults. Cancer 71:2585-2597
12. Prados MD, Gutin PH, Phillips TL et al (1992) Highly Anaplastic Astrocytoma: A review of 357 patients treated between 1977 and 1989. Int J Radiat Oncol Biol Phys 23:3-8
13. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578
14. Yung WKA, Mechtler L, Gleason MJ (1991) Intravenous carboplatin for recurrent malignant gliomas: A phase II study. J Clin Oncol 9:860
15. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M et al (1999) Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17:2762-2771
16. Longee DC, Friedman HS, Albright RE, Burger PC et al (1990) Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. J Neurosurg 72:583-588
17. Chamberlain MC, Tsao-Wei D (2004) Recurrent glioblastoma multiforme: salvage therapy with cyclophosphamide. Cancer 100:1213-1220
18. Brem H, Piantadosi S, Burger PC, Walker M, Selker R et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008-1012
19. Jaeckle KA, Hess KR, Yung A et al (2003) Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: A North American Brain Tumor Consortium study. J Clin Oncol 21:2305-2311
20. Soffieti R, Nobile M, Rida F et al (2004) Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV chemotherapy: A phase II study. Cancer 15:807-813
21. Brandes AA, Basso U, Vastola F et al (2003) Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: A phase II study. Ann Oncol 14:1727-1731
22. Triebels VH, Taphoorn MJ, Brandes AA et al (2004) Salvage PCV chemotherapy for temozolomide resistant oligodendrogliomas. Neurology 63:904-906
23. Batchelor TT, Gilbert MR, Supko JG et al (2004) Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11. Neuro Oncol 6:21-27
24. Buckner JC, Reid JM, Wright K et al (2003) Irinotecan in the treatment of glioma patients: Current and future studies of the North Cancer Central treatment Group. Cancer 97:2352-2358
25. Chamberlain MC (2002) Salvage chemotherapy with CPT-11 for recurrent glioblastoma. J Neurooncol 56:183-188
26. Cloughesy TF, Filka E, Kuhn J et al (2003) Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every 3-week regimen. Cancer 97:2381-2386
27. Friedman HS, Petros WP, Friedman AH et al (1999) Irinotecan therapy in adults with progressive malignant glioma. J Clin Oncol 17:1516-1525
28. Prados MD, Yung WKA, Jaeckle KA et al (2004) Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. Neuro Oncol 6:44-54
29. Prados MD, Lamborn K, Yung WKA et al (2006) A Phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. Neuro Oncol 8(2):189-193
30. Gilbert MR, Supko JG, Batchelor T et al (2003) A Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 9:2940-2949
31. Macdonald DR, Cascino TL, Schold SC et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
32. Miller RG Jr (1981) Survival Analysis. Wiley, New York, pp 114-118
33. Pike MC (1972) Contribution to the discussion on the paper by R. Peto and J. Peto, 'Asymptotically efficient rank invariant procedures'. J R Stat Soc Ser A 135:201-203
34. Berry G, Kitchin RM, Mock PA (1991) A comparison of two simple hazard ratio estimators based on the logrank test. Stat Med 10:749-755
35. Lawless JF (1982) Statistical models and methods for lifetime data. Wiley, New York, pp 345-354
36. Kaplan EL, Meier P (1958) Nonparametric estimation form incomplete observations. J Am Stat Assoc 53:457-481
37. Mantel N (1963) Chi-square tests with one degree of freedom: Extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 58:690-700
38. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748
39. van den Bent M, Brandes M, Frenay P et al (2005) Multicenter phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma, anaplastic astrocytoma and low grade astrocytoma: An EORTC new drug development group and brain tumor group study. J Clin Oncol A3:118S (suppl: abstr 1528)
40. Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Oncology Group trial 9402. J Clin Oncol 24(18):2707-2714
41. Stupp R, Mason WP, Van Den Bent MJ et al (2004) Concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme. Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trial Groups. J Clin Oncol 22:1S
42. Triebels VH, Taphoorn MJ, Brandes AA et al (2004) PCV chemotherapy for temozolomide resistant oligodendrogliomas. Neurology 63:904-906
43. Jaeckle KA, Ballman RD, Jenkins RB, Buckner JC (2006) Current strategies in treatment of oligodendroglioma: Evolution of molecular signatures of response. J Clin Oncol 24(8):1246-1252
44. Vrendenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253-1259